🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

NEW Neuropsychopharmacology paper out from the Liechti group comparing R-MDMA, S-MDMA, and racemic MDMA in healthy humans 👇

NEW PAPER 💊 A low (not micro) dose of LSD (26 µg) reduced EEG responses to neutral and happy faces, suggesting that low doses of LSD could alter emotional processing in the brain. #Neuroscience #LSDResearch #EEG liebertpub.com/doi/abs/10.108…

🚨New Paper🚨 We explored pharmacological and extra-pharmacological predictors of the #psychedelic #LSD experience!Dose is key! Personality traits, mood, and pre-drug states are also major influencers! Sex and body weight? Not so much! Patrick Vizeli nature.com/articles/s4139…

New paper published in JAMA Psychiatry: A meta-analysis of adverse events in trials of classic psychedelics suggests an overall favorable safety profile. However, serious adverse events, while rare, did occur. It highlights ways to improve the detection and reporting of adverse events

I'm happy to be part of the 37th ECNP Congress, 21-24 September. Join my poster P1037 on #LSD-assisted theapy in anxiety, at poster session on 22/09/24, 12:35 - 14:00. Programme: ecnp.eu/congress-progr… See you in Milan! #ECNP2024 @ECNPtweets #psychiatry #psychedelics

Congratulations to @PsyMihai and all other co-authors on investigating the shared and distinct connectivity properties of three prototypical psychoactive compounds. Classic #psychedelics seem to go their own way :) !

It's today! If you're in Milan and interested in #psychedelics stop by! #ECNP

We're creeping up to 10,000 followers! 🤩 We hope to make it there ahead of #ACNP2024, so if you don't follow us yet, maybe you'll consider it? 🤔 Of course, we're not above a little bribery 😏 The follower who takes us to 10k will get some fun ACNP & Neuropsychopharmacology swag 😎

When your paper makes it to the cover but they mix up first and last author 💔

Instead of waiting on US presidential election results, consider spending the day with cutting-edge mental health science in Zürich. Tomorrow, Nov 6 from 9:30 onwards at the University Hospital of Psychiatry

Honoured to be one of this year's Swiss Society of Biological Psychiatry (SSBP) Young investigator award recipients! Thank you!

Our latest research dives into the potential mechanism of #MDMA induced hyponatremia and identifies #oxytocin as potential key factor. Good news: fluid restriction migitates the risk!

Join us in congratulating Neuropsychopharmacology’s new Editorial Intern, Friederike Holze 👏👏

So excited to welcome Friederike Holze to the NPP Special Projects team! 🥳

Super excited to join the team!!🎉🔥

In honor of Black History Month, we will share NPP resources for Black & URM trainees, re-visit evidence-based NPP articles showing the impacts of systemic racism & highlight Black NPP authors & ACNP members who are improving our communities through research & advocacy 👇

Our latest research describes the treatment of a patient with neuropathic pain who was successfully treated with low-dose #MDMA #psychedelics frontiersin.org/journals/psych…

It's time for another recap of what's new #ThisWeekInNPP See below for Neuropsychopharmacology papers on novel treatments for youth cannabis use disorder, interactions between opioid receptor availability & family environment, and factors contributing to postpartum depression ⤵️

Check out what's new #ThisWeekInNPP See below for new insights into mechanisms underpinning clozapine's effects, interactions between methamphetamine & serotonin, and neural signatures of late-life depression ⤵️

🔬🧠International experts such as Katrin Preller, Guy Goodwin, david erritzoe, Friederike Holze Friederike Holze, Amandine Luquiens, Lea Mertens Lea Mertens, Christian Lüscher, Mickael Naassila Recherche alcool and Matthias Liechti will present the latest news regarding #psychedelics.